## Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 4

INFINITY PHARMACEUTICALS, INC. Form 4 November 02, 2016 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to **SECURITIES** Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **BLOCH LAWRENCE E** Issuer Symbol INFINITY PHARMACEUTICALS, (Check all applicable) INC. [INFI] (Last) (First) (Middle) 3. Date of Earliest Transaction Director X\_Officer (give title (Month/Day/Year) below) C/O INFINITY 10/31/2016 EVP, CFO & CBO PHARMACEUTICALS, INC., 784 MEMORIAL DRIVE (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check .. . . . .

January 31, Expires: 2005 Estimated average burden hours per response...

OMB

Number:

**OMB APPROVAL** 

10% Owner

Other (specify

below)

3235-0287

0.5

(Print or Type Responses)

|                     | Filed(Month/Day/Year)  |                    |            |                      |        |              | Applicable Line)<br>_X_ Form filed by One Reporting Person |              |              |  |
|---------------------|--|--------------------|------------|----------------------|--------|--------------|--|--------------|--------------|--|
| CAMBRIDGE, MA 02139 |  |                    |            |                      |        |              | Form filed by More than One Reporting<br>Person            |              |              |  |
| (City)              | (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |                    |            |                      |        |              |  |              |              |  |
| 1.Title of          | 2. Transaction Date  | 2A. Deemed         | 3.         | 4. Securit           | ies Ac | quired       | 5. Amount of   | 6. Ownership | 7. Nature of |  |
| Security            | (Month/Day/Year)   | Execution Date, if | Transactio | on(A) or Disposed of |        |              | Securities   | Form: Direct | Indirect     |  |
| (Instr. 3)          |  | any                | Code       | (D)                  |        | Beneficially | (D) or   | Beneficial   |              |  |
|                     |  | (Month/Day/Year)   | (Instr. 8) | (Instr. 3, 4 and 5)  |        |              | Owned  | Indirect (I) | Ownership    |  |
|                     |  |                    |            |                      |        |              | Following  | (Instr. 4)   | (Instr. 4)   |  |
|                     |  |                    |            |                      | (A)    |              | Reported   |              |              |  |
|                     |  |                    |            |                      | or     |              | Transaction(s)   |              |              |  |
|                     |  |                    | Code V     | Amount               | (D)    | Price        | (Instr. 3 and 4)   |              |              |  |
| Common<br>Stock     | 10/31/2016   |                    | А          | 39,039<br>(1)        | А      | \$0          | 41,905   | D            |              |  |
| Common<br>Stock     |  |                    |            |                      |        |              | 4,877.88   | Ι            | 401(k)       |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactio<br>Code<br>(Instr. 8) | 5.<br>onNumber<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | Expiration D<br>(Month/Day,<br>e |                    |       | le and<br>int of<br>rlying<br>ities<br>. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Nu<br>Deriv<br>Secu<br>Bene<br>Owne<br>Follo<br>Repo<br>Trans<br>(Instr |
|---|---|---|---|--|---|----------------------------------|--------------------|-------|---|---|--|
|   |   |   |   | Code V                                 | (A) (D)   | Date<br>Exercisable              | Expiration<br>Date | Title | Amount<br>or<br>Number<br>of<br>Shares            |   |  |

## **Reporting Owners**

| Reporting Owner Name / Address  |                | Relationships |           |                |       |  |  |  |
|---|----------------|---------------|-----------|----------------|-------|--|--|--|
|   |                | Director      | 10% Owner | Officer        | Other |  |  |  |
| BLOCH LAWRENCE E<br>C/O INFINITY PHARMAC<br>784 MEMORIAL DRIVE<br>CAMBRIDGE, MA 02139 | EUTICALS, INC. |               |           | EVP, CFO & CBO |       |  |  |  |
| Signatures  |                |               |           |                |       |  |  |  |
| Lawrence E.<br>Bloch  | 11/02/2016     |               |           |                |       |  |  |  |

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation (1)Committee of our Board of Directors, such shares vested in full on October 31, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.